In Annex VI to Regulation (EC) No 1272/2008, Table 3 of Part 3 is amended as follows:

the following entries are inserted:

Index No	Chemical name	EC No	CAS No	Classification		Labelling			Specific Conc. Limits, M-factors and ATE	Notes
				Hazard Class and Category Code(s)	Hazard statement Code(s)	Pictogram, Signal Word Code(s)	Hazard statement Code(s)	Suppl. Hazard statement Code(s)
‘007-030-00-3	nitric acid …% [C ≤ 70 %]	231-714-2	7697-37-2.	Ox. Liq. 3 Acute Tox. 3 Skin Corr. 1A	H272 H331 H314	GHS03 GHS06 GHS05 Dgr	H272 H331 H314	EUH071	Ox. Liq. 3; H272: C ≥ 65 % inhalation: ATE = 2,65 mg/L (vapours) Skin Corr. 1A; H314: C ≥ 20 % Skin Corr. 1B; H314: 5 % ≤ C < 20 %	B’
‘014-048-00-5	silicon carbide fibres (with diameter < 3 μm, length > 5 μm and aspect ratio ≥ 3:1)	206-991-8	409-21-2 308076-74-6	Carc. 1B	H350i	GHS08 Dgr	H350i’
‘014-049-00-0	trimethoxyvinylsilane; trimethoxy(vinyl)silane	220-449-8	2768-02-7	Skin Sens. 1B	H317	GHS07 Wng	H317’
‘014-050-00-6	tris(2-methoxyethoxy)vinylsilane; 6-(2-methoxyethoxy)-6-vinyl-2,5,7,10-tetraoxa-6-silaundecane	213-934-0	1067-53-4	Repr. 1B	H360FD	GHS08 Dgr	H360FD’
‘016-098-00-3	dimethyl disulphide	210-871-0	624-92-0	Flam. Liq. 2 Acute Tox. 3 Acute Tox. 3 STOT SE 3 STOT SE 1 Eye Irrit. 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1	H225 H331 H301 H336 H370 (upper respiratory tract, inhalation) H319 H317 H400 H410	GHS02 GHS06 GHS08 GHS09 Dgr	H225 H331 H301 H336 H370 (upper respiratory tract, inhalation) H319 H317 H410		inhalation: ATE = 5 mg/L (vapours) oral: ATE = 190 mg/kg bw M = 1 M = 10’
‘029-024-00-X	granulated copper; [particle length: from 0,9 mm to 6,0 mm; particle width: from 0,494 to 0,949 mm]	231-159-6	7440-50-8	Aquatic Chronic 2	H411	GHS09	H411’
‘029-025-00-5	bis(N-hydroxy-N-nitrosocyclohexylaminato-O,O’)copper; bis(N-cyclohexyl-diazenium-dioxy)-copper; [Cu-HDO]	239-703-4	312600-89-8 15627-09-5	Flam. Sol. 1 Acute Tox. 4 STOT RE 2 Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1	H228 H302 H373 (liver) H318 H400 H410	GHS02 GHS07 GHS08 GHS05 GHS09 Dgr	H228 H302 H373(liver) H318 H410		oral: ATE = 360 mg/kg bw M = 1 M = 1’
‘050-031-00-9	dioctyltin dilaurate; [1] stannane, dioctyl-, bis(coco acyloxy) derivs. [2]	222-883-3 [1] 293-901-5 [2]	3648-18-8 [1] 91648-39-4 [2]	Repr. 1B STOT RE 1	H360D H372 (immune system)	GHS08 Dgr	H360D H372 (immune system)’
‘601-092-00-0	dibenzo[def,p]chrysene; dibenzo[a,l]pyrene	205-886-4	191-30-0	Carc. 1B Muta. 2	H350 H341	GHS08 Dgr	H350 H341		Carc. 1B; H350: C ≥ 0,001 %’
‘603-237-00-3	ipconazole (ISO); (1RS,2SR,5RS;1RS,2SR,5SR)-2-(4-chlorobenzyl)-5-isopropyl-1-(1H-1,2,4-triazol-1-ylmethyl)cyclopentanol	-	125225-28-7 115850-69-6 115937-89-8	Repr. 1B Acute Tox. 4 STOT RE 2 Aquatic Chronic 1	H360D H302 H373 (eyes, skin, liver) H410	GHS08 GHS07 GHS09 Dgr	H360D H302 H373 (eyes, skin, liver) H410		oral: ATE = 500 mg/kg bw M = 100’
‘603-238-00-9	bis(2-(2-methoxyethoxy)ethyl)ether; tetraglyme	205-594-7	143-24-8	Repr. 1B	H360FD	GHS08 Dgr	H360FD’
‘603-239-00-4	paclobutrazol (ISO); (2RS,3RS)-1-(4-chlorophenyl)-4,4-dimethyl-2-(1H-1,2,4-triazol-1-yl)pentan-3-ol	-	76738-62-0	Repr. 2 Acute Tox. 4 Acute Tox. 4 Eye Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1	H361d H332 H302 H319 H400 H410	GHS08 GHS07 GHS09 Wng	H361d H332 H302 H319 H410		inhalation: ATE = 3,13 mg/L (dusts or mists) oral: ATE = 490 mg/kg bw M = 10 M = 10’
‘603-240-00-X	2,2-bis(bromomethyl)propane-1,3-diol	221-967-7	3296-90-0	Carc. 1B Muta. 1B	H350 H340	GHS08 Dgr	H350 H340’
‘603-241-00-5	geraniol; (2E)-3,7-dimethylocta-2,6-dien-1-ol	203-377-1	106-24-1	Skin Sens. 1	H317	GHS07 Wng	H317’
‘605-041-00-3	2-(4-tert-butylbenzyl)propionaldehyde	201-289-8	80-54-6	Repr. 1B	H360Fd	GHS08 Dgr	H360Fd’
‘607-738-00-8	MCPA-thioethyl (ISO); S-ethyl (4-chloro-2-methylphenoxy)ethanethioate; S-ethyl 4-chloro-o-tolyloxythioacetate	246-831-4	25319-90-8	Acute Tox. 4 STOT RE. 2 Aquatic Acute 1 Aquatic Chronic 1	H302 H373 (liver) H400 H410	GHS07 GHS08 GHS09 Wng	H302 H373 (liver) H410		oral: ATE = 450 mg/kg bw M = 10 M = 10’
‘607-740-00-9	diisooctyl phthalate	248-523-5	27554-26-3	Repr. 1B	H360FD	GHS08 Dgr	H360FD’
‘607-741-00-4	4-{[(6-chloropyridin-3-yl)methyl](2,2-difluoroethyl)amino}furan-2(5H)-one; flupyradifurone	-	951659-40-8	Acute Tox. 4 STOT RE 2 Aquatic Acute 1 Aquatic Chronic 1	H302 H373 (muscle) H400 H410	GHS07 GHS08 GHS09 Wng	H302 H373 (muscle) H410		oral: ATE = 500 mg/kg bw M = 10 M = 10’
‘607-742-00-X	thiencarbazone-methyl (ISO); methyl 4-[(4,5-dihydro-3-methoxy-4-methyl-5-oxo-1H-1,2,4-triazol-1-yl)carbonylsulfamoyl]-5- methylthiophene-3-carboxylate	-	317815-83-1	Aquatic Acute 1 Aquatic Chronic 1	H400 H410	GHS09 Wng	H410		M = 1000 M = 1000’
‘607-743-00-5	L-(+)-lactic acid; (2S)-2-hydroxypropanoic acid	201-196-2	79-33-4	Skin Corr. 1C Eye Dam. 1	H314 H318	GHS05 Dgr	H314	EUH071’
‘607-744-00-0	2-methoxyethyl acrylate	221-499-3	3121-61-7	Flam. Liq. 3 Muta. 2 Repr. 1B Acute Tox. 3 Acute Tox. 4 Skin Corr. 1C Eye Dam. 1 Skin Sens. 1	H226 H341 H360FD H331 H302 H314 H318 H317	GHS02 GHS05 GHS06 GHS08 Dgr	H226 H341 H360FD H331 H302 H314 H317	EUH071	inhalation: ATE = 2,7 mg/L (vapours) oral: ATE = 404 mg/kg bw’
‘607-745-00-6	glyoxylic acid …%	206-058-5	298-12-4	Eye Dam. 1 Skin Sens. 1B	H318 H317	GHS05 GHS07 Dgr	H318 H317			B’
‘607-746-00-1	sodium N-(hydroxymethyl)glycinate; [formaldehyde released from sodium N-(hydroxymethyl)glycinate]	274-357-8	70161-44-3	Carc. 1B Muta. 2 Acute Tox. 4 Acute Tox. 4 STOT SE 3 Skin Irrit. 2 Eye Irrit. 2 Skin Sens. 1	H350 H341 H332 H302 H335 H315 H319 H317	GHS08 GHS07 Dgr	H350 H341 H332 H302 H335 H315 H319 H317		inhalation: ATE = 3 mg/L (dusts or mists) oral: ATE = 1100 mg/kg bw	8 9’
‘611-181-00-6	potassium (oxido-NNO-azoxy)cyclohexane; cyclohexylhydroxydiazene 1-oxide, potassium salt; [K-HDO]	-	66603-10-9	Flam. Sol. 1 Acute Tox. 3 STOT RE 2 Skin Irrit. 2 Eye Dam. 1 Aquatic Chronic 2	H228 H301 H373 (liver) H315 H318 H411	GHS02 GHS06 GHS08 GHS05 GHS09 Dgr	H228 H301 H373 (liver) H315 H318 H411		oral: ATE = 136 mg/kg bw’
‘612-294-00-3	mecetronium etilsulfate; N-ethyl-N,N-dimethylhexadecan-1-aminium ethyl sulfate; mecetronium ethyl sulphate; [MES]	221-106-5	3006-10-8	Skin Corr. 1 Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1	H314 H318 H400 H410	GHS05 GHS09 Dgr	H314 H410	EUH071	M = 100 M = 1000’
‘613-331-00-6	(2RS)-2-[4-(4-chlorophenoxy)-2-(trifluoromethyl)phenyl]-1-(1H-1,2,4-triazol-1-yl)propan-2-ol; mefentrifluconazole	-	1417782-03-6	Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1	H317 H400 H410	GHS07 GHS09 Wng	H317 H410		M = 1 M = 1’
‘613-332-00-1	oxathiapiprolin (ISO); 1-(4-{4-[5-(2,6-difluorophenyl)-4,5-dihydro-1,2-oxazol-3-yl]-1,3-thiazol-2-yl}piperidin-1-yl)-2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]ethanone	-	1003318-67-9	Aquatic Chronic 1	H410	GHS09 Wng	H410		M = 1’
‘613-333-00-7	pyrithione zinc; (T-4)-bis[1-(hydroxy-.kappa.O)pyridine-2(1H)-thionato-.kappa.S]zinc	236-671-3	13463-41-7	Repr. 1B Acute Tox. 2 Acute Tox. 3 STOT RE 1 Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1	H360D H330 H301 H372 H318 H400 H410	GHS08 GHS06 GHS05 GHS09 Dgr	H360D H330 H301 H372 H318 H410		inhalation: ATE = 0,14 mg/L (dusts or mists) oral: ATE = 221 mg/kg bw M = 1000 M = 10’
‘613-334-00-2	flurochloridone (ISO); 3-chloro-4-(chloromethyl)-1-[3-(trifluoromethyl)phenyl]pyrrolidin-2-one	262-661-3	61213-25-0	Repr. 1B Acute Tox. 4 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1	H360FD H302 H317 H400 H410	GHS08 GHS07 GHS09 Dgr	H360FD H302 H317 H410		oral: ATE = 500 mg/kg bw M = 100 M = 100’
‘613-335-00-8	4,5-dichloro-2-octyl-2H-isothiazol-3-one; [DCOIT]	264-843-8	64359-81-5	Acute Tox. 2 Acute Tox. 4 Skin Corr. 1 Eye Dam. 1 Skin Sens. 1A Aquatic Acute 1 Aquatic Chronic 1	H330 H302 H314 H318 H317 H400 H410	GHS06 GHS05 GHS09 Dgr	H330 H302 H314 H317 H410	EUH071	inhalation: ATE = 0,16 mg/L (dusts or mists) oral: ATE = 567 mg/kg bw Skin Irrit. 2; H315: 0,025 % ≤ C < 5 % Eye Irrit. 2; H319: 0,025 % ≤ C < 3 % Skin Sens. 1A; H317: C ≥ 0,0015 % M = 100 M = 100’
‘613-336-00-3	2-methyl-1,2-benzothiazol-3(2H)-one; [MBIT]	-	2527-66-4	Acute Tox. 4 Acute Tox. 3 Skin Corr. 1C Eye Dam. 1 Skin Sens. 1A Aquatic Acute 1 Aquatic Chronic 2	H312 H301 H314 H318 H317 H400 H411	GHS06 GHS05 GHS09 Dgr	H312 H301 H314 H317 H410	EUH071	dermal: ATE = 1100 mg/kg bw oral: ATE = 175 mg/kg bw Skin Sens. 1A; H317: C ≥ 0,0015 % M = 1’
‘616-228-00-4	3-(difluoromethyl)-1-methyl-N-(3',4',5'-trifluorobiphenyl-2-yl)pyrazole-4-carboxamide; fluxapyroxad	-	907204-31-3	Lact. Aquatic Acute 1 Aquatic Chronic 1	H362 H400 H410	GHS09 Wng	H362 H410		M = 1 M = 1’
‘616-230-00-5	N-(hydroxymethyl)acrylamide; methylolacrylamide; [NMA]	213-103-2	924-42-5	Carc. 1B Muta. 1B STOT RE 1	H350 H340 H372 (peripheral nervous system)	GHS08 Dgr	H350 H340 H372 (peripheral nervous system)’
‘616-231-00-0	5-fluoro-1,3-dimethyl-N-[2-(4-methylpentan-2-yl)phenyl]-1H-pyrazole-4-carboxamide; 2'-[(RS)-1,3-dimethylbutyl]-5-fluoro-1,3-dimethylpyrazole-4-carboxanilide; penflufen	-	494793-67-8	Carc. 2 Aquatic Acute 1 Aquatic Chronic 1	H351 H400 H410	GHS08 GHS09 Wng	H351 H410		M = 1 M = 1’
‘616-232-00-6	iprovalicarb (ISO); isopropyl [(2S)-3-methyl-1-{[1-(4-methylphenyl)ethyl]amino}-1-oxobutan-2-yl]carbamate	-	140923-17-7	Carc. 2	H351	GHS08 Wng	H351’
‘616-233-00-1	silthiofam (ISO); N-allyl-4,5-dimethyl-2-(trimethylsilyl)thiophene-3-carboxamide	-	175217-20-6	STOT RE 2 Aquatic Chronic 2	H373 H411	GHS08 GHS09 Wng	H373 H411’
‘650-057-00-6	Margosa, ext. [cold-pressed oil of Azadirachta indica seeds without shells extracted with super-critical carbon dioxide]	283-644-7	84696-25-3	Aquatic Chronic 3	H412		H412’

the entries corresponding to index numbers 007-004-00-1; 014-018-00-1; 015-134-00-5; 015-181-00-1; 050-021-00-4; 050-027-00-7; 082-013-00-1; 603-014-00-0; 603-065-00-9; 605-019-00-3; 607-177-00-9; 607-256-00-8; 607-314-00-2; 609-041-00-4; 609-064-00-X; 613-112-00-5; 613-115-00-1; 613-125-00-6; 613-202-00-4; 613-259-00-5; 616-014-00-0 and 617-006-00-X are replaced by the following entries respectively:

Index No	Chemical name	EC No	CAS No	Classification		Labelling			Specific Conc. Limits, M-factors and ATE	Notes
				Hazard Class and Category Code(s)	Hazard statement Code(s)	Pictogram, Signal Word Code(s)	Hazard statement Code(s)	Suppl. Hazard statement Code(s)
‘007-004-00-1	nitric acid …% [C > 70 %]	231-714-2	7697-37-2	Ox. Liq. 2 Acute Tox. 1 Skin Corr. 1A	H272 H330 H314	GHS03 GHS06 GHS05 Dgr	H272 H330 H314	EUH071	Ox. Liq. 2; H272: C ≥ 99 % Ox. Liq. 3; H272: 70 % ≤ C < 99 %	B’
‘014-018-00-1	octamethylcyclotetrasiloxane; [D4]	209-136-7	556-67-2	Repr. 2 Aquatic Chronic 1	H361f *** H410	GHS08 GHS09 Wng	H361f *** H410		M = 10’
‘015-134-00-5	pirimiphos-methyl (ISO); O-[2-(diethylamino)-6-methylpyrimidin-4-yl] O,O-dimethyl phosphorothioate	249-528-5	29232-93-7	Acute Tox. 4 STOT RE 1 Aquatic Acute 1 Aquatic Chronic 1	H302 H372 (nervous system) H400 H410	GHS07 GHS08 GHS09 Dgr	H302 H372 (nervous system) H410		oral: ATE = 1414 mg/kg bw M = 1000 M = 1000’
‘015-181-00-1	phosphine	232-260-8	7803-51-2	Flam. Gas 1 Press. Gas Acute Tox. 1 Skin Corr. 1B Aquatic Acute 1	H220 H330 H314 H400	GHS02 GHS04 GHS06 GHS05 GHS09 Dgr	H220 H330 H314 H400		inhalation: ATE = 10 ppmV (gases)	U’
‘050-021-00-4	dichlorodioctylstannane	222-583-2	3542-36-7	Repr. 1B Acute Tox. 2 STOT RE 1 Aquatic Chronic 3	H360D H330 H372 ** H412	GHS08 GHS06 Dgr	H360D H330 H372 ** H412		Repr. 1B; H360 D: C ≥ 0,03 % inhalation: ATE = 0,098 mg/L (dusts or mists)’
‘050-027-00-7	2-ethylhexyl 10-ethyl-4,4-dioctyl-7-oxo-8-oxa-3,5-dithia-4-stannatetradecanoate; [DOTE]	239-622-4	15571-58-1	Repr. 1B STOT RE 1 Aquatic Acute 1 Aquatic Chronic 1	H360D H372 (immune system) H400 H410	GHS08 GHS09 Dgr	H360D H372 (immune system) H410’
‘082-013-00-1	lead powder; [particle diameter < 1 mm]	231-100-4	7439-92-1	Repr. 1A Lact. Aquatic Acute 1 Aquatic Chronic 1	H360FD H362 H400 H410	GHS08 GHS09 Dgr	H360FD H362 H410		Repr. 1A; H360D: C ≥ 0,03 % M = 1 M = 10’
‘603-014-00-0	2-butoxyethanol; ethylene glycol monobutyl ether	203-905-0	111-76-2	Acute Tox. 4* Acute Tox. 4 Skin Irrit. 2 Eye Irrit. 2	H332 H302 H315 H319	GHS07 Wng	H332 H302 H315 H319		oral: ATE = 1200 mg/kg bw’
‘603-065-00-9	m-bis(2,3-epoxypropoxy)benzene; resorcinol diglycidyl ether	202-987-5	101-90-6	Carc. 1B Muta. 2 Acute Tox. 3 Acute Tox. 4 Skin Irrit. 2 Eye Irrit. 2 Skin Sens. 1 Aquatic Chronic 3	H350 H341 H311 H302 H315 H319 H317 H412	GHS08 GHS06 Dgr	H350 H341 H311 H302 H315 H319 H317 H412		dermal: ATE = 300 mg/kg bw oral: ATE = 500 mg/kg bw’
‘607-177-00-9	tribenuron-methyl (ISO); methyl 2-[N-(4-methoxy-6-methyl-1,3,5-triazin-2-yl)-N-methylcarbamoylsulfamoyl]benzoate	401-190-1	101200-48-0	STOT RE 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1	H373 H317 H400 H410	GHS08 GHS07 GHS09 Wng	H373 H317 H410		M = 100 M = 100’
‘607-256-00-8	azoxystrobin (ISO); methyl (E)-2-{2-[6-(2-cyanophenoxy)pyrimidin-4-yloxy]phenyl}-3-methoxyacrylate	-	131860-33-8	Acute Tox. 3 Aquatic Acute 1 Aquatic Chronic 1	H331 H400 H410	GHS06 GHS09 Dgr	H331 H410		inhalation: ATE = 0,7 mg/L (dusts or mists) M = 10 M = 10’
‘607-314-00-2	ethofumesate (ISO); (RS)-2-ethoxy-2,3-dihydro-3,3-dimethylbenzofuran-5-yl methanesulfonate	247-525-3	26225-79-6	Aquatic Acute 1 Aquatic Chronic 1	H400 H410	GHS09 Wng	H410		M = 1 M = 1’
‘609-041-00-4	2,4-dinitrophenol	200-087-7	51-28-5	Acute Tox. 3 * Acute Tox. 3 Acute Tox. 2 STOT RE 1 Aquatic Acute 1	H331 H311 H300 H372 H400	GHS06 GHS08 GHS09 Dgr	H331 H311 H300 H372 H400		dermal: ATE = 300 mg/kg bw oral: ATE = 30 mg/kg bw’
‘609-064-00-X	mesotrione (ISO); 2-[4-(methylsulfonyl)-2-nitrobenzoyl]-1,3-cyclohexanedione	-	104206-82-8	Repr. 2 STOT RE 2 Aquatic Acute 1 Aquatic Chronic 1	H361d H373 (eyes, nervous system) H400 H410	GHS08 GHS09 Wng	H361d H373 (eyes, nervous system) H410		M = 10 M = 10’
‘613-112-00-5	octhilinone (ISO); 2-octyl-2H-isothiazol-3-one; [OIT]	247-761-7	26530-20-1	Acute Tox. 2 Acute Tox. 3 Acute Tox. 3 Skin Corr. 1 Eye Dam. 1 Skin Sens. 1A Aquatic Acute 1 Aquatic Chronic 1	H330 H311 H301 H314 H318 H317 H400 H410	GHS06 GHS05 GHS09 Dgr	H330 H311 H301 H314 H317 H410	EUH071	inhalation: ATE = 0,27 mg/L (dusts or mists) dermal: ATE = 311 mg/kg bw oral: ATE = 125 mg/kg bw Skin Sens. 1A; H317: C ≥ 0,0015 % M = 100 M = 100’
‘613-115-00-1	hymexazol (ISO); 3-hydroxy-5-methylisoxazole	233-000-6	10004-44-1	Repr. 2 Acute Tox. 4 Eye Dam. 1 Skin Sens. 1 Aquatic Chronic 2	H361d H302 H318 H317 H411	GHS08 GHS07 GHS05 GHS09 Dgr	H361d H302 H318 H317 H411		oral: ATE = 1600 mg/kg bw’
‘613-125-00-6	hexythiazox (ISO); trans-5-(4-chlorophenyl)-N-cyclohexyl-4-methyl-2-oxo-3-thiazolidine-carboxamide	-	78587-05-0	Aquatic Acute 1 Aquatic Chronic 1	H400 H410	GHS09 Wng	H410		M = 1 M = 1’
‘613-202-00-4	pymetrozine (ISO); (E)-4,5-dihydro-6-methyl-4-(3-pyridylmethyleneamino)-1,2,4-triazin-3(2H)-one	-	123312-89-0	Carc. 2 Repr. 2 Aquatic Chronic 1	H351 H361fd H410	GHS08 GHS09 Wng	H351 H361fd H410		M = 1’
‘613-259-00-5	imiprothrin (ISO); reaction mass of: [2,4-dioxo-(2-propyn-1-yl)imidazolidin-3-yl]methyl(1R)-cis-chrysanthemate; [2,4-dioxo-(2-propyn-1-yl)imidazolidin-3-yl]methyl(1R)-trans-chrysanthemate	428-790-6	72963-72-5	Carc. 2 Acute Tox. 4 Acute Tox. 4 STOT SE 2 Aquatic Acute 1 Aquatic Chronic 1	H351 H332 H302 H371 (nervous system; oral, inhalation) H400 H410	GHS08 GHS07 GHS09 Wng	H351 H332 H302 H371 (nervous system; oral, inhalation) H410		inhalation: ATE = 1,4 mg/L (dusts or mists) oral: ATE = 550 mg/kg bw M = 10 M = 10’
‘616-014-00-0	butanone oxime; ethyl methyl ketoxime; ethyl methyl ketone oxime	202-496-6	96-29-7	Carc. 1B Acute Tox. 4 Acute Tox. 3 STOT SE 3 STOT SE 1 STOT RE 2 Skin Irrit. 2 Eye Dam. 1 Skin Sens. 1	H350 H312 H301 H336 H370 (upper respiratory tract) H373 (blood system) H315 H318 H317	GHS08 GHS06 GHS05 Dgr	H350 H312 H301 H336 H370 (upper respiratory tract) H373 (blood system) H315 H318 H317		dermal: ATE = 1100 mg/kg bw oral: ATE = 100 mg/kg bw’
‘617-006-00-X	bis(α,α-dimethylbenzyl) peroxide	201-279-3	80-43-3	Org. Perox. F Repr. 1B Skin Irrit. 2 Eye Irrit. 2 Aquatic Chronic 2	H242 H360D H315 H319 H411	GHS02 GHS08 GHS07 GHS09 Dgr	H242 H360D H315 H319 H411’

the entries corresponding to index numbers 601-064-00-8 and 607-693-00-4 are deleted.